It is made available under a CC-BY-NC-ND 4.0 International license .

1

## An Analysis of SARS-CoV-2 Vaccine Breakthrough Infections and Associated Clinical Outcomes

Heather Kerwin, MPH<sup>1</sup>; Rex Briggs, BS<sup>2</sup>; Sameer Nair-Desai, BA<sup>3</sup>; Andrew Gorzalski, PhD<sup>4</sup>; Mark Pandori, PhD<sup>4</sup>; Stefanie Friedhoff<sup>3</sup>; Thomas C. Tsai, MD MPH<sup>5</sup>

**Corresponding Author**: Heather Kerwin, MPH, 1001 East Ninth Street, Building B, Reno, NV, 89512 (<a href="https://hkerwin@washoecounty.us">hkerwin@washoecounty.us</a>)

<sup>&</sup>lt;sup>1</sup>Washoe County Health District

<sup>&</sup>lt;sup>2</sup>Ad Council

<sup>&</sup>lt;sup>3</sup>Brown School of Public Health

<sup>&</sup>lt;sup>4</sup>Nevada State Public Health Laboratory

<sup>&</sup>lt;sup>5</sup>Department of Health Policy and Management, Harvard T.H. Chan School of Public Health

It is made available under a CC-BY-NC-ND 4.0 International license .

2

## **Abstract**

Understanding the rate and clinical features associated with vaccine breakthrough infections (VBT) is of critical public health importance. Recent evidence on VBT in Barnstable County, Massachusetts, has prompted guidance on masking for vaccinated individuals in areas of high community-level transmission. Additional data is needed to better understand the prevalence and rate of VBT infections. Using detailed disease investigation data from Washoe County, Nevada we sought to assess the rate of symptomatic infection and serious illness among VBT cases compared to non-vaccinated individuals with COVID-19. From February 12 - July 29, 2021, the Washoe County Health District identified and traced 6,128 out of 6,399 reported cases across the sample period. 338 (5.5%) of all cases were identified as breakthrough infections, and 289 (86%) vaccinated individuals had symptomatic infections. Severe clinical outcomes were infrequent with 17 hospitalizations (5% of VBT) and no deaths. Cycle threshold values were not statistically different between vaccinated and unvaccinated individuals.


3

## [Text]

As the Delta variant causes a new surge of SARS-CoV-2 cases in the US, understanding the rate and clinical features associated with vaccine breakthrough infections (VBT) among those already vaccinated is of critical public health importance. To analyze the prevalence and features of breakthrough infections, we utilize sequencing and case data on Washoe County, Nevada from the Washoe County Health District and Nevada State Public Health Laboratory (NSPHL). Between February 12th and July 29th, 2021, the Washoe County Health District (WCHD) reported 6,399 new cases of COVID-19, and successfully traced 6,128 of these (95.8%) back to their sources (data updated as of August 3<sup>rd</sup>). Out of the 6,399 cases, the Health District identified 339 (5.5%) as breakthrough infections. One case was removed due to data inconsistencies, for a final N = 338. VBT cases were defined as any positive RT-PCR test for individuals fully vaccinated for 14 days or more, prior to symptom onset or routine testing. One observation was removed due to data quality, for a final sample of 338 cases. The WCHD collected individual-level data for VBT cases (N = 338), including demographics (age; sex; gender; race/ethnicity); clinical data (vaccine type and dosage schedule; symptom onset; hospitalization or death); and information on Ct-values and variants of interest, primarily from the NSPHL and, in rare instances, from other partner laboratories. Mann-Whitney U tests and Chi-squared or Fisher exact tests were used to assess differences in demographic features and outcomes associated with VBT and non-VBT cases.

Between February 12th and July 29th, VBT accounted for a small share of total infections (**Figure 1**). The 338 reported VBT cases represent 0.14% of Washoe's vaccinated population of across the study period, compared to a 2.54% rate in those unvaccinated.

Figure 1. SARS-CoV-2 infections by date reported and vaccination status — Washoe County, Nevada



Severe outcomes in vaccinated individuals were also rare. Out of the 5,961 traced cases, 289 (86%) vaccinated individuals presented with symptomatic infections, but only 17 were hospitalized (5%) and none died. Hospitalizations mostly occurred among elderly individuals. However, elderly people were less prone to breakthrough infections and more likely to present without symptoms compared to younger age groups (**Table 1**).

Table 1. SARS-CoV-2 infections and clinical outcomes by key demographics — Washoe County, Nevada

Demographic Features <sup>a</sup>	County-Level Statistics <sup>b</sup>	No. of VBT Cases (N = 338)	No. of Non-VBT Cases (N = 6,061)	P-Values (VBT vs. Non-VBT)
Gender				
Male	230,091/456,936 (50.4%)	142/338 (42.0%)	3,085/6,059 (50.9%)	p < 0.01
Female	226,845/456,936 (49.6%)	196/338 (58.0%)	2,974/6,059 (49.1%)	
Age				
0 – 19 Years	110,387/456,936 (24.2%)	10/338 (3.0%)	1,264/6,059 (20.9%)	p < 0.01
20 – 39 Years	127,124/456,936 (27.8%)	118/338 (34.9%)	2,458/6,059 (40.6%)	
40 – 59 Years	116,670/456,936 (25.5%)	102/338 (30.2%)	1,607/6,059 (26.5%)	
60 – 79 Years	88,672/456,936 (19.4%)	92/338 (27.2%)	639/6,059 (10.6%)	
80+ Years	14,083/456,936 (3.1%)	16/338 (4.7%)	91/6,059 (1.5%)	
Race				
White	354,407/456,936 (77.6%)	270/318 (84.9%)	3,400/3,942 (86.3%)	p = 0.18
Black	10,630/456,936 (2.3%)	11/318 (3.5%)	254/3,942 (6.4%)	
Asian	24,401/456,936 (5.3%)	20/318 (6.3%)	245/3,942 (6.2%)	
Other	37,237/456,936 (8.2%)	17/318 (5.4%)	43/3,942 (1.1%)	
Ethnicity				
Hispanic	111,653/456,936 (24.4%)	53/317 (16.7%)	1,564/6,059 (25.8%)	p < 0.01
Not Hispanic	345,283/456,936 (75.6%)	264/317 (83.3%)	4,495/6,059 (74.2%)	
Outcomes				
Symptomatic		289/338 (85.5%)	5,448/5,789 (94.8%)	p < 0.01
Hospitalized		17/338 (5.0%)	411/5,789 (7.2%)	p = 0.15
Deaths		0/338 (0%)	58/6,061 (1.0%)	p = 0.27

Out of 80 breakthrough cases sequenced from June - July 2021, 76 were associated with the Delta variant (95%). Breakthrough infections sequenced as the Delta variant had a median Ct-value of 20 (Q1 = 16; Q3 = 24; N = 77); while non-Delta breakthrough infections had a

<sup>&</sup>lt;sup>a</sup> Did not include the "Other" category for Gender, the "Age Unknown" category for Age, or the "Unknown" category for Ethnicity. County-level case data does not differentiate between Hispanic and non-Hispanic, so all race bins include those who identify either as Hispanic or non-Hispanic. Only the largest race bins have been displayed. White, Black, Asian, and Other account for 94.09% of the VBT sample (N = 319), and 64.71% of cases in Washoe County (N = 3.927). For the VBT data, Ethnicity is only tabulated for individuals in the above racial bins. County-level clinical outcomes of symptomatic and hospitalized individuals only reported for traced cases across the sample period (N = 5.961).

<sup>&</sup>lt;sup>b</sup> Reported as overall county-level demographics from the 5-year 2015-2019 ACS. As a result, population values are slightly lower than current county reporting (ACS reports 456,936, Washoe reports 478,155 as of August 3rd, 2021).

median of 21 (Q1 = 18; Q3 = 26; N = 27). Across all variants, vaccinated individuals presented similar Ct-values to unvaccinated individuals. Those fully vaccinated with an infection reported median values of 22 (Q1 = 17; Q3 = 26; N = 120), while median Ct-values for those unvaccinated were 21 (Q1 = 17; Q3 = 25; N = 797). The Kruskal-Wallis test returned a p-value of 0.8259, indicating no significant differences.

In this case series analysis from Washoe County, Nevada, the rate of breakthrough infections was more than 18-fold lower than the rate of infections among unvaccinated individuals. Most importantly, rates of severe illness were low in vaccinated individuals. These findings add to a growing body of data that can reassure the public on the real-world effectiveness of the COVID-19 vaccines.<sup>2</sup>

Our findings should be interpreted in light of key limitations. Early data still undergoing investigation suggests increasing rates of VBTs. Our VBT sample is not representative due to shifts in testing behavior and availability. Despite these limitations, this analysis adds to existing literature outlining the risks of VBTs and emphasizes the need for health authorities to monitor evolving trends in vaccine breakthrough data.

It is made available under a CC-BY-NC-ND 4.0 International license.

Author Contributions: Heather Kerwin had full access to all of the data in the study and takes

responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Kerwin, Briggs, Pandori, Gorzalski

Data acquisition, analysis, or interpretation: Kerwin, Nair-Desai, Briggs, Gorzalski

7

Drafting of the manuscript: Nair-Desai, Friedhoff, Tsai

Critical revision of the manuscript: Kerwin, Briggs, Pandori, Gorzalski

Statistical analysis: Nair-Desai, Tsai, Briggs

Conflict of Interest Disclosures: All authors have completed ICJME forms disclosing conflicts

of interest in relation to this study. No conflicts of interest were reported.

Funding Disclosures: The Washoe County Health District and the Nevada State Health

Laboratory report funding from the CDC for work unrelated to this manuscript. Thomas Tsai

reports funding from William F. Milton Fund of Harvard University, the Massachusetts

Consortium on Pathogen Readiness underwritten by the Massachusetts Life Sciences Center, The

Commonwealth Fund, and Arnold Ventures for work unrelated to this manuscript.

**Additional Contributions:** The authors would like to acknowledge Elena Varganova of the

Washoe County Health District for biostatistical support and the Washoe County Health District

COVID-19 disease investigators for data collection, as well as Stefanie Vanhooser from the

Nevada State Public Health Laboratory for data collection and research support.

**Additional Information:** All data utilized in this analysis are available upon request.


**Ethics Decision:** This study has been deemed exempt from IRB/HRPP review by the Brown University Institutional Review Board, as it does not classify as Human Subjects Research.

## References

- Brown, Catherine M., et al. "Outbreak of SARS-CoV-2 Infections, Including Covid-19
   Vaccine Breakthrough Infections, Associated with Large Public Gatherings Barnstable
   County, Massachusetts, July 2021." MMWR. Morbidity and Mortality Weekly Report,
   vol. 70, no. 31, 2021, doi:10.15585/mmwr.mm7031e2.
- 2. Musser, James M., et al. "Delta Variants OF SARS-COV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 Cases in Houston, Texas." MedRxiv, 1 Aug. 2021, doi:10.1101/2021.07.19.21260808.

1

Figure 1. SARS-CoV-2 infections by date reported and vaccination status — Washoe County, Nevada<sup>a</sup>



<sup>&</sup>lt;sup>a</sup> Calculated new cases do not perfectly align with reported cases (6,456 in Figure 1 vs. 6,399 reported) due to minor changes in county-level case reporting.

It is made available under a CC-BY-NC-ND 4.0 International license.

1

Table 1. SARS-CoV-2 infections and clinical outcomes by key demographics — Washoe County, Nevada

Demographic Features <sup>a</sup>	County-Level Statistics <sup>b</sup>	No. of VBT Cases (N = 338)	No. of Non-VBT Cases (N = 6,061)	P-Values (VBT vs. Non-VBT)
Gender				
Male	230,091/456,936 (50.4%)	142/338 (42.0%)	3,085/6,059 (50.9%)	p < 0.01
Female	226,845/456,936 (49.6%)	196/338 (58.0%)	2,974/6,059 (49.1%)	
Age				
0-19 Years	110,387/456,936 (24.2%)	10/338 (3.0%)	1,264/6,059 (20.9%)	p < 0.01
20 – 39 Years	127,124/456,936 (27.8%)	118/338 (34.9%)	2,458/6,059 (40.6%)	
40-59 Years	116,670/456,936 (25.5%)	102/338 (30.2%)	1,607/6,059 (26.5%)	
60 – 79 Years	88,672/456,936 (19.4%)	92/338 (27.2%)	639/6,059 (10.6%)	
80+ Years	14,083/456,936 (3.1%)	16/338 (4.7%)	91/6,059 (1.5%)	
Race	, , , ,			
White	354,407/456,936 (77.6%)	270/318 (84.9%)	3,400/3,942 (86.3%)	p = 0.18
Black	10,630/456,936 (2.3%)	11/318 (3.5%)	254/3,942 (6.4%)	
Asian	24,401/456,936 (5.3%)	20/318 (6.3%)	245/3,942 (6.2%)	
Other	37,237/456,936 (8.2%)	17/318 (5.4%)	43/3,942 (1.1%)	
Ethnicity				
Hispanic	111,653/456,936 (24.4%)	53/317 (16.7%)	1,564/6,059 (25.8%)	p < 0.01
Not Hispanic	345,283/456,936 (75.6%)	264/317 (83.3%)	4,495/6,059 (74.2%)	
Outcomes			ì	
Symptomatic		289/338 (85.5%)	5,448/5,789 (94.8%)	p < 0.01
Hospitalized		17/338 (5.0%)	411/5,789 (7.2%)	p = 0.15
Deaths		0/338 (0%)	58/6,061 (1.0%)	p = 0.27

<sup>&</sup>lt;sup>a</sup> Did not include the "Other" category for Gender, the "Age Unknown" category for Age, or the "Unknown" category for Ethnicity. County-level case data does not differentiate between Hispanic and non-Hispanic, so all race bins include those who identify either as Hispanic or non-Hispanic. Only the largest race bins have been displayed. White, Black, Asian, and Other account for 94.09% of the VBT sample (N = 319), and 64.71% of cases in Washoe County (N = 3.927). For the VBT data, Ethnicity is only tabulated for individuals in the above racial bins. County-level clinical outcomes of symptomatic and hospitalized individuals only reported for traced cases across the sample period (N = 5.961).

<sup>&</sup>lt;sup>b</sup> Reported as overall county-level demographics from the 5-year 2015-2019 ACS. As a result, population values are slightly lower than current county reporting (ACS reports 456,936, Washoe reports 478,155 as of August 3rd, 2021).